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Abstract
Background: Cancers are complex diseases arising from accumulated genetic mutations that disrupt intracellular
signaling networks. While several predisposing genetic mutations have been found, these individual mutations
account only for a small fraction of cancer incidence and mortality. With large-scale measurement technologies,
such as single nucleotide polymorphism (SNP) microarrays, it is now possible to identify combinatorial effects that
have significant impact on cancer patient survival.
Results: The identification of synergetic functioning SNPs on genome-scale is a computationally daunting task and
requires advanced algorithms. We introduce a novel algorithm, Geninter, to identify SNPs that have synergetic
effect on survival of cancer patients. Using a large breast cancer cohort we generate a simulator that allows
assessing reliability and accuracy of Geninter and logrank test, which is a standard statistical method to integrate
genetic and survival data.
Conclusions: Our results show that Geninter outperforms the logrank test and is able to identify SNP-pairs with
synergetic impact on survival.
Introduction
Cancer is a complex disease that develops from accumu-
lated genetic mutations that impair cellular processes
responsible for maintaining homeostasis. For instance,
inherited breast cancer predisposition is currently thought
to result from rare high penetrance mutations in high risk
families, or multiplicative effects of moderate penetrance
variants or common low risk variants in the population
[1,2]. So far, over 20 low penetrance variants, such as sin-
gle nucleotide polymorphisms (SNPs), have been identified
but they only explain approximately 8% of the familial risk
of breast cancer, with the high and moderate penetrance
genes explaining roughly 25% [3,4]. Combinatorial effects
of large numbers of putative risk alleles are likely to be
important in further explaining the genetic risk for breast
cancer [5]. Increasing evidence suggests that not only
breast cancer risk but also prognosis is inherited, and
germline variants have been found to associate with survi-
val of cancer patients [6]. Furthermore, interactive survival
effects of genetic variants from cancer pathways have also
been implicated [7], and survival effects detected for speci-
fic genotype carriers after defined chemotherapy treatment
indicate treatment resistance conferred by inherited
genetic variation [8]. However, few studies up to now have
analyzed genome-wide the combinatorial survival effects
of polymorphisms interacting with each other or with clin-
ical features [7,9,10]. The large-scale analysis of interactive
effects between genetic markers, or between genetic mar-
kers and clinical variables, will be important in increasing
our understanding of diseases like cancer [11]. Uncovering
these combinatorial survival effects will provide new mar-
kers for clinical decision making and personalized treat-
ment of cancer patients [5].
Identification of markers that have combinatorial survi-
val effect requires an iterative systems biology approach
with efficient computational methodology which can be
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executed on high-performance computing clusters [12].
Here we introduce a novel algorithm, Geninter, for disco-
vering interacting SNPs with combinatorial survival
effect, i.e., SNPs that individually have no survival effect
but together contribute significantly to survival. Previous
efforts in discovering specific combinatorial genotypes
have focused on small, highly selected groups of SNPs
[9,10], and to our knowledge Geninter is the first algo-
rithm that is able to systematically integrate SNP-pairs
with survival data on a genome-wide scale.
Methods
Genome-wide analysis of pair-wise SNPs brings forward
two major challenges. First, the combination of multiple
marker genotypes increases the number of groups in the
survival analysis. The major consequences of the increased
number of groups are that (i) the number of samples
should be relatively high in order to ensure stable esti-
mates in the subgroups, and (ii) the increase in the num-
ber of survival curves leads to more intersections of the
curves, which renders the logrank statistic less reliable
[13]. This issue is exacerbated by the tendency of the log-
rank test to overestimate large cohorts to have significant
survival differences even when the difference is only slight.
Second, SNP microarrays produce states for hundreds of
thousands or millions of markers making evaluation of all
the pairs computationally intensive [11]. Geninter
addresses the computational challenges with optimized
code and distributed programming. The overall outline of
Geninter is given in Figure 1. Here we provide details on
how each step in Geninter is executed. First, an attribute
matrix containing genotypes and a matrix of survival
times are given as an input to Geninter. The analysis is
divided into three steps: (1) determining the distance
matrix based on the genotype combination specific
Kaplan-Meier curves; (2) using hierarchical clustering to
determine the underlying relative structure of the curves;
and (3) computing the rank. If the rank of a SNP-pair
exceeds a chosen threshold, the pair is considered as
a putative survival affecting combination and stored.
The user can define the threshold parameter based on
the number of SNP-pairs or p-value cutoff. We have
implemented Geninter so that it can be run as an indivi-
dual program but also on Anduril bioinformatics workflow
engine that allows advanced processing of the Geninter
results, such as automated annotation (e.g., linkage dise-
quilibrium (LD) mapping) from bio-databases [14].
Determining the distance matrix
The first stage of Geninter is the calculation of a distance
matrix D for a family of Kaplan-Meier survival curves. A
family of curves is the set of curves for which one instance
of the statistic is calculated. The Kaplan-Meier estimate
for surviving to at least time tj is equal to the conditional
probability of surviving beyond tj multiplied by the esti-
mate at the previous time point tj−1. At time 0, all patients
are alive. The area between curves was chosen as the dis-
tance metric because it is (1) robust to possible erratic
behavior of curve functions, and (2) computationally sim-
ple. Let C = {c1, c2, ..., cm} be a set of m survival curves.
For example, for a SNP-pair, m Î [1,9] since there are
three alleles for each SNP (e.g., AA, AB and BB) and thus
9 possible combinations of alleles. Let cj and ck be survival
curves and cj, ck Î C. For every time point ti, where i Î [2,
n] and n is the total number of time points available in fol-
low-up, we calculate the distance between the survival
curves as
D(cj, ck) =
n∑
i=2
(ti − ti−1)|Scj(i) − Sck(i)|, (1)
where Scj(i) = cj(ti−1) and Sck(i) = ck(ti−1) denote the
survival rates of the curves cj and ck at the given time
point. To determine the distance matrix for a family of
survival curves, all pairwise distances D (cj, ck) are calcu-
lated to form the distance matrix D. D can be thought
to correspond to the sum of areas of rectangles
(ti, Scj(i)), (ti, Scj(i)), (ti−1, Sck(i)), (ti−1, Sck(i)), ∀i ∈ [2, n].
Hierarchical clustering
In the second stage, curves in a family are clustered by
complete linkage agglomerative hierarchical clustering
using D as the distance matrix. The main benefit of the
Figure 1 The outline of the Geninter analysis workflow. First, an attribute matrix containing genotypes and a matrix of survival times are
given as an input to Geninter. The analysis is divided into three steps. The results (sorted list of SNP-pairs) can then be 12 annotated, for
instance, using the Ensembl database and filtered to exclude markers that are in linkage disequilibrium (LD). The output contains the marker
pairs, their ranks and p-values.
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hierarchical clustering is a dendrogram in which leafs
are clusters, the leafs contain biological information
which can be taken advantage of, and the clusters repre-
sent survival curves (Figure 2). In the complete linkage
the distances between two clusters are calculated as the
maximum distance between any object in the first and
any object in the second cluster. We chose complete
linkage clustering over single or average linkage because
it more effectively distinguishes curves that are farthest
away from one another. However, Geninter allows its
user to define any alternative method supported by the
underlying clustering library.
Cluster tree distance
Curves in a curve family correspond to unique combina-
tions of features (e.g., alleles). Each combination of features
contains e features constrained by e domains respectively
(e.g., SNP markers). Formally, a curve cj corresponds to a
tuple of features (aj,1, aj,2, . . . , aj,e) over the cartesian
product of the feature domains A1 × A2 × . . . × Ae. For
the set of curves C = {c1, c2, . . . , cm} and its corresponding
feature combinations we define its attributes Mj, 1 ≤ j ≤ e
as vectors such that Mj = (a1,j, a2,j, . . . , am,j). In other
words, for each domain Aj we define its attribute Mj which
represents features from the domain Aj corresponding to
all the curves from C.
For example, let us have two SNP markers such that
SNP1 has one allele BB and SNP2 has two alleles AA
and AB. Thus, we have two domains A1 = {BB} and
A2 = {AA, AB}. We can have the following SNP-pair
combinations
SNP1(M1) SNP2(M2)
c1 BB
c2 BB
AA
AB
(2)
In this way, for SNP1 we have attribute M1 = (BB, BB)
and for SNP2 we have attribute M2 = (AA, AB).
Figure 2 Cluster tree dendrogram for a family of curves and the distance of two alleles. The features (alleles) circled in blue satisfy the
equivalence relation. The allele combinations circled in green and red have a distance of |Hmax − H2|. The height of each leaf node is the height
of its parent. This is marked with the blue dashed lines for the circled leafs.
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In general, we can represent combinations of e fea-
tures corresponding to m curves as a matrix:
M =
⎛⎜⎜⎜⎝
a1,1 a1,2 · · · a1,e
a2,1 a2,2 · · · a2,e
...
...
. . .
...
am,1 am,2 · · · am,e
⎞⎟⎟⎟⎠ = (MT1 MT2 · · · MTe ) ,
For each attribute Mk, 1 ≤ k ≤ e we establish the
equivalence relation between curves cj1, cj2 ∈ C as follows:
cj1≡Mkcj2 if and only if aj1k = aj2k. For example, the two
allele combinations (BB, AA) and (BB, AB) share the fea-
ture BB in their attribute M1 for which we can define the
equivalence relation c1≡M1c2 (see Figures 3 and 2). Let
EMj be a set of equivalence classes for ≡Mj and let EMj
have lj equivalence classes
{
E1,j,E2,j, · · · ,El,j
}
(note that
lj ≤ m). We can define the distance within an equivalence
class with the cluster dendrogram.
Let H1 be the height in the dendrogram tree of the
cluster nearest to cj1 and H2 similarly for cj2. Hmax is
defined as the height in the dendrogram of the smallest
cluster (last common ancestor) into which both cj1 and
cj2 belong. Then, provided that cj1 , cj2 ∈ C and cj1≡Mjcj2,
the distance between two curves in the cluster tree is
d(cj1 , cj2 ) =
⎧⎪⎪⎨⎪⎪⎩
|Hmax −H1 −H2| if Hmax = H1,Hmax = H2
|Hmax −H1| if Hmax = H2
|Hmax −H2| if Hmax = H1
0 if Hmax = H1 = H2
(3)
One possible distance d that satisfies the equivalence
relation is shown in Figure 2. The distance d in the
family of survival curves does not exceed the maximum
survival rate 1.0 multiplied by the last time point, i.e.,
0 ≤ d ≤ tn.
Now, we can define the maximal distance between
two curves in the equivalence class Ek,j
dEk,j = maxcj1,cj2∈ Ek,j
(d(cj1, cj2)). (4)
Rank calculation
Every curve depicts the survival of a group sharing a com-
bination of attributes. For example, the SNP-combinations
(BB, AA) and (BB, AB) contain the attributes (BB, BB) and
(BB, AB) as depicted in Matrix 2. The rank of a single
attribute is the maximum of its cluster tree distances that
satisfy the equivalence relation. In the final step, we calcu-
late one rank for each attribute, sum the attribute ranks,
and compute the final rank as the average of these partial
ranks.
The partial rank corresponding to an attribute (i.e., the
rank of a single marker or other attribute) over all
curves is defined by the maximum distance of all the
different equivalence classes
RMj = max
Ek,j∈EMj
(dEk,j). (5)
Given the last time point tn, the rank of the family of
survival curves is the sum of all the partial ranks
R¯ =
∑e
j=1 RMj
etn
. (6)
For example, the rank of two markers SNP1 and SNP2 is
R¯ =
(RSNP1 + RSNP2)
2tn
.
Figure 3 Combinatorial genotypic survival effect. Combination of two markers reveals synergetic effect on survival. The panel inside each
figure contains the genotypes and sample sizes. In the right hand survival image, the curve furthest apart (BB, BB) from the rest is for the first
marker most distant from curve (BB, AA) and for the second marker from curve (AB, BB).
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This formulation of the rank allows us to extend the
algorithm to multiple combinations of attributes. More-
over, the attributes are not constrained to be SNP-markers
or clinical variables but can be anything for which we can
define an equivalence relation.
Rank distribution
In order to study the properties of the Geninter rank
distribution, we generated a data set with 1,000 patients,
140 markers, and uniformly distributed survival times.
Under the null hypothesis of “no survival effect”, we
observed that the density function of the rank distribu-
tion could be approximated by a gamma distribution.
We tested altogether 18 statistical distributions including
Gaussian, log-normal and binomial. The best fitting dis-
tribution using log-likelihood was the three-parameters
generalized extreme value distribution followed by the
two-parameter gamma distribution. As the gamma distri-
bution consisted of only two parameters, we chose that
to represent the data. The gamma distribution approxi-
mation enables us to compute p-values in constant time
for every rank statistic.
Assume that the rank R¯ is a Gamma distributed ran-
dom variable. Then R¯ ∼ (k, θ), where k and θ are the
shape and scale, respectively. Let μˆ be the sample mean
of the distribution and σˆ 2 the sample variance. Since the
maximum likelihood estimator for the scale parameter
is θˆ = μˆk , and it is known that σˆ
2 = kθˆ2 = k( μˆk )
2 = μˆ
2
k
, it
follows that
k =
μ̂2
σ̂ 2
, θˆ =
μˆ
σˆ 2
.
The rank distribution is sensitive to the population
size. Therefore, we suggest that the scale and shape
parameters are calibrated in respect to the population
size. The calibration can be achieved by recalculating θˆ
and k for the new null rank distribution.
Implementation
We have implemented Geninter in the R statistical lan-
guage, and in Fortran using the Message Passing Inter-
face (MPI) for parallelization [15]. The Fortran/MPI
implementation was developed and tested with a HP
CP4000 BL ProLiant cluster system of CSC - IT Center
for Science Ltd. utilizing the IMSL Fortran Math library
for survival computations. Both implementations of the
algorithm are freely available at the project website
http://csbi.ltdk.helsinki.fi/pub/geninter.
Breast cancer data description
Genotype data were obtained on Finnish breast cancer
patients genotyped as described previously [16]. Briefly,
the patient set comprised two series of unselected breast
cancer patients and additional familial cases diagnosed
at the Helsinki University Central Hospital (HUCH).The
first patient set was collected in 1997-1998 and 2000
and covers 79% of all consecutive, newly diagnosed
cases during the collection periods [17,18]. The second
set, containing newly diagnosed patients, was gathered
in 2001-2004 and covers 87% of all breast cancer
patients treated at HUCH during the collection period
[8]. Additional familial cases were collected as described
in [19].
Results
Cancer genotype-survival simulator
To assess whether Geninter is able to detect true and false
positive SNP-pairs we generated a simulator based on
1,000 breast cancer samples chosen from a cohort of
breast cancer patients and controls genotyped on the
HumanHap550 SNP microarrays [16]. We estimated the
genotype frequencies using these 1,000 samples and ran-
domly chosen 150 SNPs. We limited our analysis to those
markers where the minor allele frequency exceeded 5%.
This resulted in 139 qualifying markers whose genotype
frequencies exceeded the threshold. The qualifying geno-
type frequencies were used as probabilities when generat-
ing the simulated markers.
We assumed that under the null hypothesis the survival
times are uniformly distributed with the maximum survi-
val of 360 months and the mean survival of 180 months.
This assumption gives results in survival curve families
with a ten year survival of approximately 75%, which is
similar to the ten year overall survival of patients diag-
nosed with breast cancer in the Nordic countries [20].
In order to introduce predetermined survival effects
into the survival times, we randomly chose two markers.
Then, samples with the combination of rare homozygotes
from both markers were assigned survival times from a
logarithmic distribution with a mean of log
(
360
16
)
. This
was then repeated for a different pair of markers in order
to create affected marker pairs as defined by the user. A
marker could only appear in one affected marker pair in
the data generation process. In order to simulate censor-
ing, which is present in all cancer cohorts, we generated
random censoring events by choosing events to occur in
80% and censoring in 20% of the samples.
Analysis and comparison of the simulated data
Logrank test is a well-established statistical method to
associate a SNP to survival. We tested both Geninter and
logrank test with the simulated data in which the ground
truth is known. Based on simulations on the effect of of
population size on rank distribution (Figure 4), we esti-
mated the background rank distribution from a simulated
cohort of 1,000 samples and used the estimated distribution
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to compute p-values for the ranks. We applied the false dis-
covery rate (FDR) procedure for the multiple hypothesis
correction of the p-values [21]. We verified that the simu-
lated distribution is similar to one calculated from a larger
run with real data (data not shown). We further varied the
size of our marker set between 40 and 140 markers. The
number of marker combinations in the simulation was
restricted to 140 because the analysis of 10,000 combina-
tions
((
140
2
))
= 9730 does not yet require a high-
performance cluster. Our simulator allows controlling the
true positives, i.e., the marker pairs whose survival times
were drawn from the logarithmic distribution.
In order to study the effect of the number of affected
markers on the rank statistic, we varied the fraction of
affected markers from 1% to 50% of the total marker
population. Figure 4 shows how increasing the ratio of
affected markers to non-affected markers shifts the rank
distribution to the right. With low numbers of affected
markers the rank distribution is nearly identical to the
background distribution. The 50% fraction represents a
pathological case where half of the marker population has
some induced survival effect and therefore every marker
pair has at least one marker with a survival effect.
We applied the Geninter and logrank methods to ana-
lyze all the combinatorial SNP-SNP survival effects in
simulated data. Additionally, we calculated the single SNP
survival effects with the logrank test. Evinced in Figure 3, a
combination acquires the rank of > 0.5 (FDR corrected p <
5.99× 10−8) even when neither marker alone exhibits
noticeable survival effect (FDR corrected p < 0.01). In
order to assess the relative performance of the Geninter
and logrank statistic, we calculated the false positive and
true positive rates for both methods when the number of
affected marker pairs was varied. The false positive rate is
the number of false positives divided by the sum of false
positives and true negatives. The true positive rate is
the number of true positives divided by the sum of true
positives and false negatives. Based on the true and false
positives, we calculated the receiver operating characteris-
tic (ROC) curves for both algorithms [22]. ROC curves
enable a direct comparison of true and false positive rates
while varying the threshold. We analyzed the behavior of
the true positive and false positive rates with independent,
simulated test data. For each of the rank vectors in Figure 5,
we executed the analysis with both algorithms. We
increased the number of affected marker pairs and recorded
the changes in true and false positives. Furthermore, we
repeated each simulation 20 times for each affected marker
pair number, and averaged the rates over these repetitions
to account for simulation variance. Both statistics were able
to identify affected marker pairs correctly. However, the
false positive rate of both methods increase along with
the number of affected markers (Figure 5). Furthermore,
the logrank statistic has a substantially worse false positive
rate indicating that most of its findings are false positives
even at very low p-value thresholds. The sharp, smooth
form of the logrank ROC curves in Figure 5 reflects the rise
of the false positive rate of the logrank test even at p-value
thresholds near zero. The p-value threshold of significance
for Geninter decreases when the proportion of affected to
non-affected markers increases. For a low ratio (less
than10%) of affected marker pairs to non-affected marker
pairs, less than 10% false positive rate and over 99% true
positive rate are achieved with the nominal p-value < 0.01.
Conclusions
We have designed and implemented a novel algorithm,
Geninter, to identify SNP-pairs with combinatorial
Figure 4 Effect of population size on rank distribution. 780 marker combinations have been evaluated for each distribution. The black
dashed curve is the hypothetical null distribution. The boxes on the right of each set of curves indicate the ratio of affected and non-affected
markers for each curve. If the ratio is 0.5, every marker combination has some induced survival effect. In the left panel population size is 10,000,
in the middle panel 1,000, and in the right panel 100.
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survival effect. Our results with simulated data, which is
based on SNP data from 1,000 breast cancer patients,
demonstrate Geninter to be both accurate and reliable.
Geninter outperforms the logrank test, which is a widely
used test for uncovering significant differences in survi-
val data. Additionally, simulations where the number of
samples was varied, indicate that Geninter results in a
good balance of true and false positives with1,000 sam-
ples, and it is applicable to cohorts with more than 500
samples (data not shown). Given the current large-scale
cancer data collection efforts, such as The Cancer Gen-
ome Atlas [23], many cancer types with thousands of
samples with SNP and clinical data will be soon avail-
able and Geninter can be directly applied to such data
sets.
In order to be able to analyze the billions of putative
SNP combinations in the large-scale data sets, we have
developed two implementations of Geninter. The R imple-
mentation allows testing and running a relatively small
number of SNPs. For instance, a run with 140 markers
and 1,000 samples takes approximately five hours with a
standard laptop. As there are 1010 SNP-SNP combinations
to be computed for approximately 550k SNPs, we provide
a Fortran implementation with the Message Passing Inter-
face (MPI) that can be run on a high-performance compu-
ter cluster. We have tested the Fortran implementation of
Geninter on a high-performance computer cluster at
CSC-IT Center for Science. Our analysis indicates that a
genome-wide analysis of all pairwise combinations of 550k
markers takes approximately 1,500 hours with 256 com-
puting nodes. The astronomical number of tests emerging
from a genome-wide pair-wise analysis basically renders
the FDR correction unpractical and useless. Thus, p-values
are used only to sort the Geninter computed ranks. We
note that Geninter is not restricted to pair-wise analysis
but is applicable to any number of combinations.
Obviously, higher order combinations require prior selec-
tion of attributes or other pre-processing methods to
reduce the search space.
The Geninter algorithm is particularly useful in situa-
tions where the number of groups or population size is
high. We have demonstrated that Geninter is able to
Figure 5 Average ROC curves for different statistics when the number of affected pairs increases. Solid lines are computed from the
Geninter rank p-values, dashed from the logrank test p-values. Results from simulations with different numbers of affected marker pairs are
drawn with different colors. Each curve is an average (averaged over 20 repetitions) of an analysis of a cohort of 10,000 samples with the
number of affected marker combinations varying between 1 and 20.
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integrate SNP-pairs to survival data. The approach, how-
ever, is applicable to other markers, such as methylation
markers and copy number variants, as well. The major
limiting factors for the use of Geninter are the availability
of data and computational power. Given a number of
large-scale efforts to quantify genetic profiles and other
markers for thousands of cancer patients and exponential
increase in computing power, we believe that Geninter
will be a useful tool to identify combinatorial survival
effects of multiple attributes, which provide a solid basis
for advanced analysis of complex disorders.
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